OKYO Pharma Accelerates Phase 3 Trial for Corneal Pain Following FDA Feedback

Key Facts

In a move that strengthens investor confidence in the biotech sector, OKYO Pharma announced it has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its lead candidate, urcosimod. According to reports, this feedback validates the company's regulatory path, effectively reducing uncertainty for its upcoming clinical milestones. The company now plans to accelerate the drug's transition into a global Phase 3 pivotal trial for the treatment of neuropathic corneal pain (NCP).

This progress comes amid high competition in the ophthalmic treatment market, where peers such as Bausch + Lomb and Kala Pharmaceuticals are also racing to develop innovative solutions for ocular pain and dry eye disease. Per market data, successfully advancing to Phase 3 is a critical milestone for small-cap biotech firms, as it paves the way for a future Biologics License Application (BLA). Urcosimod is positioned as a potential alternative for patients who do not find adequate relief from current standard-of-care treatments.

Looking ahead to the economic calendar, broader sentiment in the healthcare sector may be influenced by the U.S. Non-Farm Payrolls report scheduled for July 2, 2026, which often impacts capital flows into growth-oriented biotech stocks.